Trials / Completed
CompletedNCT00052013
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether PTK787/ZK 222584 is effective in treating hemangioblastoma of the brain and/or retina in patients with von Hippel-Lindau disease. The study will also assess safety and tolerability of PTK787/ZK 222584, and changes in markers of angiogenesis (new blood vessel growth).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PTK787/ZK 222584 |
Timeline
- Start date
- 2003-02-01
- Primary completion
- 2006-06-01
- First posted
- 2003-01-22
- Last updated
- 2017-03-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00052013. Inclusion in this directory is not an endorsement.